GLP1R and metabolic dysfunction-associated steatotic liver disease: <h4>Objective</h4>In the present network meta-analysis (NMA), we aimed to compare the effectiveness of daily and weekly treatment with glucagon-like peptide-1 receptor agonists for patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM).<h4>Method</h4>We used Stata 17.0 for the NMA.